We noticed you are on our UK page. Want to switch regions? Choose from the options:

Clinical trials

We’re committed to advancing medicine by finding new and improved ways to diagnose and treat cancer that deliver better life outcomes for patients across the world

Ongoing clinical trials

Cancer

The Tidal study

Lymphoma

A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

Cancer

Checkmate 7DX

Prostate cancer

A Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer - CheckMate 7DX

Cancer

Multiple Myeloma Study C16029

Myeloma

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Cancer

The Coastal Study

Haematology

A Phase 3, Randomized, Open-Label, Controlled Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma

Cancer

MCL study

Mantle Cell Lymphoma

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Cancer

MK-1026

Haematology

A Phase 2/3 Relapsed and/or Refractory Multiple Myeloma study

Cancer

Assure

Haematology

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia

Cancer

DCISionRT® Registry

Breast cancer DCIS

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

Cancer

Multiple Myeloma study CC-220

Myeloma

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Cancer

Bruin CLL 321

Haematology

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated CLL/Small Lymphocytic Lymphoma

Cancer

Greco2

Pancreatic cancer

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Breast cancer

LIT study

Breast cancer

Evaluation of LIT test as a marker for immunocompetence in chemotherapy